Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
31. |
ECCT/17/05/04 | Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI WALTER REED KERICHO |
View |
32. |
ECCT/17/05/03 | TDF IVR-002 Study Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002) |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya Partners in Health Research & Development (Thika Partners Clinical Trial Site) |
View |
33. |
ECCT/17/04/01 | Odón Device for assisted vaginal delivery Feasibility, safety and preliminary efficacy study of a new device (Odón Device) for assisted vaginal delivery |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya Kenyatta National Hospital |
View |
34. |
ECCT/16/11/02 | IMPAACT P1093 Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents |
Principal Investigator(s) 1. Lucy Koech Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME |
View |
35. |
ECCT/16/08/03 | IMPAACT 2001 A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed project |
View |